Agilent Announces Alissa Interpret Selected by North West Genomic Laboratory Hub for Clinical Genomic Analysis
December 03 2020 - 8:00AM
Business Wire
Agilent Technologies Inc. (NYSE: A) today announced its clinical
informatics platform Alissa Interpret has been adopted by the North
West Genomic Laboratory Hub (NW GLH) based in Manchester and
Liverpool, part of Manchester University NHS Foundation Trust,
England. The NW GLH and its partners are responsible for delivering
genomic testing across the whole of the North West. Alissa
Interpret, which enables clinical genetics labs to standardize and
automate variant triage, review, classification, and reports on NGS
data, becomes one of two platforms the NW GLH will use to analyze
genomics data.
With sequencing data becoming increasingly important in the
clinical environment, there is a growing need for analysis
solutions that provide results quickly and accurately. Confidence
in results is key in a clinical setting, along with the ability to
analyze large numbers of samples, as many labs are scaling NGS
tests into routine practice and thus need a solution to scale with
them. Alissa Interpret is designed to increase certainty, minimize
error, reduce the time-to-answer, and improve consistency of
results and accuracy, no matter the throughput.
"Next-generation sequencing produces huge amounts of data in
applications across cancer and human genetics, yet the complexity
related to interpreting genomic variants continues to be a
challenge,” said Kevin Meldrum, vice president and general manager
of genomics at Agilent. “We developed Alissa Interpret to increase
efficiency through standardization and enable informed decisions
with a single-workflow variant assessment for both inherited
disease and somatic assays, including SNPs, indels, CNVs, LOH, and
translocations/fusion genes.”
Interpretation and actionability of NGS data are key factors in
the adoption and success of NGS testing within the clinical market.
Agilent SureSelect custom NGS panels allow customers like the NW
GLH to precisely define target regions that are clinically
relevant. Alissa Interpret increases efficiency and diagnostic
yield by combining SNV, CNV, and fusion gene data on a single
platform and seamless integration with LIMS and BioIT
pipelines.
“It is important for us to implement a variant interpretation
software system that is both compatible with the latest ACMG
classification guidelines and supports the interpretation of rare
genomic variants in the context of the patient’s clinical symptoms.
The ability to use a single system to analyze both constitutional
variations in the context of rare diseases and somatic variants
detected in our cancer genomics services is highly desirable,” said
Ronnie Wright, Clinical Scientist at the NW GLH, Manchester
University NHS Foundation Trust.
“Moreover, given that each new observation of a genomic variant
adds to the knowledge of its association with disease, it is
essential that the system allows us to see the latest cumulative
assessment of a variant and the relevant information associated
with its interpretation to help us deliver the most accurate
results,” Wright added.
Alissa Interpret is the product of choice for interpreting and
validating NGS-based tests for rare diseases, as well as somatic
and hematologic oncology. It incorporates a number of enabling
features, such as clinical database integration, including
phenotypic information and the latest ACMG classification
guidelines, internal cohort analysis, lab-specific private
database, and version control.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets, delivering
insight and innovation towards improving the quality of life.
Agilent instruments, software, services, solutions, and people
provide trusted answers to customers' most challenging questions.
The company generated revenue of $5.34 billion in fiscal 2020 and
employs 16,400 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201203005115/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024